Joseph Kim, MD, on Liquid Biopsies as a Diagnostic for GI Cancers


The chief of surgical oncology at the UK Markey Cancer Center discussed liquid biopsies and their potential importance for diagnosing gastric cancer.

Joseph Kim, MD, chief of the division of surgical oncology at the UK Markey Cancer Center, spoke about the importance of liquid biopsies, specifically in gastric cancer, at the 2020 Gastrointestinal Cancers Symposium, held January 23-25, in San Francisco, California. 



Currently, liquid biopsies are really in their infancy in diagnostics for (gastrointestinal) cancers, especially gastric cancer. Liquid biopsies are being tested in a number of cancers, but I think it’s particularly important for gastric cancer where it may be difficult to get enough tissue to do all of the genetic testing that we need, and so the liquid biopsies provide an avenue for us to get that data which would potentially help change the type of treatments that are offered for patients with gastric cancer. 

Related Videos
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Tanio S. Bekaii-Saab, MD, on Potential of Dual Targeting to Transform Treatment of HER2+ CRC